Filtered By:
Condition: Cholesterol
Nutrition: Diets
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud,
Azita Talasaz,
Anurag Mehta,
Michael Kelly,
Evan M. Sisson,
John D. Bucheit,
Roy Brown,
Dave L. Dixon Tags: REVIEW Source Type: research
Endothelial PHACTR1 Promotes Endothelial Activation and Atherosclerosis by Repressing PPAR γ Activity Under Disturbed Flow in Mice
CONCLUSIONS: Our results identified endothelial PHACTR1 as a novel PPARγ corepressor to promote atherosclerosis in disturbed flow regions. Endothelial PHACTR1 is a potential therapeutic target for atherosclerosis treatment.PMID:37199156 | DOI:10.1161/ATVBAHA.122.318173
Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 18, 2023 Category: Cardiology Authors: Dongyang Jiang Hao Liu Guofu Zhu Xiankai Li Linlin Fan Faxue Zhao Chong Xu Shumin Wang Yara Rose Jordan Rhen Ze Yu Yiheng Yin Yuling Gu Xiangbin Xu Edward A Fisher Junbo Ge Yawei Xu Jinjiang Pang Source Type: research
Excessive exogenous cholesterol activating intestinal LXR α-ABCA1/G5/G8 signaling pathway can not reverse atherosclerosis in ApoE < sup > -/- < /sup > mice
CONCLUSION: In a high-cholesterol environment, the intestine promotes the excretion of cholesterol from the cell through the LXRα-ABCA1/G5/G8 pathway, reduces the intestinal intake of a variety of exogenous cholesterol, and reduces the risk of AS.PMID:37061692 | DOI:10.1186/s12944-023-01810-6
Source: Atherosclerosis - April 15, 2023 Category: Cardiology Authors: Xichao Yu Xue Ding Han Feng Yunhui Bi Yu Li Jinjun Shan Huimin Bian Source Type: research
Inclisiran: A Review in Hypercholesterolemia
AbstractInclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet. It is intended for use in patients unable to reach LDL-C goals on maximally tolerated statin therapy, with or without other lipid-lowering therapies (LLTs). In patients who are statin intolerant or for whom a statin is contraindi...
Source: American Journal of Cardiovascular Drugs - March 4, 2023 Category: Cardiology Source Type: research
SIRT6 regulates endothelium-dependent relaxation by modulating nitric oxide synthase 3 (NOS3)
CONCLUSIONS: We identified SIRT6 as a new regulator of the activity of NOS3, with functional implications for endothelial-dependent relaxation.PMID:36720357 | DOI:10.1016/j.bcp.2023.115439
Source: Biochemical Pharmacology - January 31, 2023 Category: Drugs & Pharmacology Authors: Jiaojiao Wang Zhiping Liu Jing Lu Jiami Zou Weile Ye Hong Li Si Gao Peiqing Liu Source Type: research
